A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals
Claudia Pisanu, Shungo Imai, Masami Tsuchiya, Mika Inoue, Keisuke Ikegami, Gianpaolo Zammarchi, Hayato Kizaki, Satoko Hori
European Journal of Clinical Pharmacology December 22, 2025 DOI: 10.1007/s00228-025-03954-z via OpenAlex
Summary
AI-generated from the abstractEsketamine, used for treatment-resistant depression, shows potential adverse effects and drug-drug interaction signals when analyzed in real-world data. The findings highlight risks that clinicians should consider when prescribing esketamine, particularly regarding possible interactions with other medications. The analysis underscores the need for careful monitoring of patients receiving esketamine to manage and mitigate these risks.
Study at a glance
| Characteristics | Observational study Peer reviewed |
|---|---|
| Intervention | Esketamine |
| Keywords | Pharmacovigilance Adverse effect Intensive care medicine Pharmacology Drug interaction |
| Citations | 3 |
| Key finding | Esketamine is associated with potential adverse effects and drug-drug interaction signals in a real-world setting. |
Abstract
Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.